Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranjini K Sundaram

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 16, 2012
Protein stains and applicationsRanjini K Sundaram, Natarajan Balasubramaniyan, Pazhani Sundaram
Recent Patents on CNS Drug Discovery|September 23, 2014
Patents on potential drugs to treat Alzheimer's disease: special emphasis on small peptidesPazhani Sundaram, Aravind K Nambiar, Ranjini K Sundaram
Current Alzheimer Research|February 22, 2008
Detoxification depot for beta-amyloid peptidesRanjini K Sundaram, Chinnaswamy Kasinathan, Stanley Stein, et al.
International Journal of Peptide Research and Therapeutics|June 20, 2012
Novel Detox Gel Depot sequesters β-Amyloid Peptides in a mouse model of Alzheimer's DiseaseRanjini K Sundaram, Chinnaswamy Kasinathan, Stanley Stein, et al.
Scientific Reports|April 7, 2022
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastomaSachita Ganesa, Amrita Sule, Ranjini K Sundaram, et al.
Translational Oncology|June 12, 2021
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivityJennifer Garbarino, Jillian Eckroate, Ranjini K Sundaram, et al.
NAR Cancer|May 24, 2021
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitorsAmrita Sule, Jinny Van Doorn, Ranjini K Sundaram, et al.
Current Protocols|February 25, 2025
Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and ImmunotherapyDeepti Bhatt, Ranjini K Sundaram, Karla S Lugo López, et al.
Journal of the American Chemical Society|March 2, 2016
Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence AssayYulia V Surovtseva, Vikram Jairam, Ahmed F Salem, et al.
Science (New York, N.Y.)|July 28, 2022
Mechanism-based design of agents that selectively target drug-resistant gliomaKingson Lin, Susan E Gueble, Ranjini K Sundaram, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|May 16, 2012
Protein stains and applicationsRanjini K Sundaram, Natarajan Balasubramaniyan, Pazhani Sundaram
Recent Patents on CNS Drug Discovery|September 23, 2014
Patents on potential drugs to treat Alzheimer's disease: special emphasis on small peptidesPazhani Sundaram, Aravind K Nambiar, Ranjini K Sundaram
Current Alzheimer Research|February 22, 2008
Detoxification depot for beta-amyloid peptidesRanjini K Sundaram, Chinnaswamy Kasinathan, Stanley Stein, et al.
International Journal of Peptide Research and Therapeutics|June 20, 2012
Novel Detox Gel Depot sequesters β-Amyloid Peptides in a mouse model of Alzheimer's DiseaseRanjini K Sundaram, Chinnaswamy Kasinathan, Stanley Stein, et al.
Scientific Reports|April 7, 2022
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastomaSachita Ganesa, Amrita Sule, Ranjini K Sundaram, et al.
Translational Oncology|June 12, 2021
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivityJennifer Garbarino, Jillian Eckroate, Ranjini K Sundaram, et al.
NAR Cancer|May 24, 2021
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitorsAmrita Sule, Jinny Van Doorn, Ranjini K Sundaram, et al.
Current Protocols|February 25, 2025
Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and ImmunotherapyDeepti Bhatt, Ranjini K Sundaram, Karla S Lugo López, et al.
Journal of the American Chemical Society|March 2, 2016
Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence AssayYulia V Surovtseva, Vikram Jairam, Ahmed F Salem, et al.
Science (New York, N.Y.)|July 28, 2022
Mechanism-based design of agents that selectively target drug-resistant gliomaKingson Lin, Susan E Gueble, Ranjini K Sundaram, et al.
Pageof 4